ClinicalTrials.gg
CompletedNCT01903460IMAGOUpdated Mar 28, 2019Results posted

Safety and Efficacy Study of LUM001 in the Treatment of Cholestatic Liver Disease in Patients With Alagille Syndrome

A Phase 2 interventional study of LUM001 and Placebo in Alagille Syndrome, sponsored by Mirum Pharmaceuticals, Inc.. Completed at 3 sites in United Kingdom. Open to participants aged 12 Months to 18 Years. Per ClinicalTrials.gov, last updated 2019-03-28.

Sponsored by Mirum Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
12 Months to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Alagille Syndrome by Mirum Pharmaceuticals, Inc. — 2 open to participants now, 2 under way, none of them phase 3. Alagille Syndrome · Mirum Pharmaceuticals, Inc..

Started
2013
with 1 other
Phase 2
6 of 10
none open now
Registered
1st of 10
by date

Among the 10 studies in Alagille Syndrome by Mirum Pharmaceuticals, Inc., this one is one of 2 that started in 2013, is one of 6 in phase 2, and was the 1st registered.

Alagille Syndrome

31 studies on the registry are indexed under Alagille Syndrome; 11 are open to participants now.

Browse Alagille Syndrome studies →

Open to participants now

2 of the 10 studies in Alagille Syndrome by Mirum Pharmaceuticals, Inc. are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 10 Alagille Syndrome studies recruiting now, 7 (70%) set no upper age limit and 3 (30%) stop at 75 or younger; 9 take children under 18; none take healthy volunteers.

This study: 12 Months to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Alagille Syndrome by Mirum Pharmaceuticals, Inc., or all of them as a file.
02

Study summary

The study is a randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of LUM001. Efficacy will be assessed by evaluating the effect of LUM001 versus placebo on the biochemical markers and pruritus associated with Alagille Syndrome.

03

Conditions studied

  • Alagille Syndrome

Browse trials for

04

Who can participate

Ages eligible
12 Months to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of Alagille Syndrome
  2. Evidence of cholestasis
  3. Moderate to severe pruritus
  4. Ability to understand and willingness to sign /assent prior to initiation of any study procedures

Exclusion criteria

Exclusion Criteria:

  1. Surgical disruption of the enterohepatic circulation
  2. Liver transplant
  3. History or presence of other concomitant liver disease
  4. Females who are pregnant or lactating
  5. Known infection
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    LUM001

    LUM001 administered orally once each day

    Drug: LUM001

  • Placebo comparator
    Placebo

    Placebo administered orally once each day

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 13 (End of Treatment) in Fasting Serum Bile Acid Level

    Participants were required to fast for at least 4 hours; only water was permitted prior to collection. A negative change from baseline indicates that the level of bile acid decreased.

    Time frame: Baseline to 13 weeks or end of treatment

Secondary outcomes

  1. Change From Baseline to Week 13 (End of Treatment) in Liver Enzymes

    Analysis of liver enzymes included alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP). A negative change from baseline indicates that the level of that enzyme decreased.

    Time frame: Baseline to 13 weeks or end of treatment

  2. Change From Baseline to Week 13 (End of Treatment) in Pruritus as Measured by The Patient And Observer Itch Reported Outcome (ItchRO) Average Daily Scores

    The ItchRO was administered as a twice daily electronic diary (eDiary). Children ≥9 years of age completed the patient ItchRO; those between the ages of 5 and 8 completed the patient ItchRO with the assistance of their caregiver. There was no patient report for subjects under the age of 5. ItchRO scores range from 0 to 4, with the higher score indicating increasing itch severity. ItchRO average daily scores were calculated as the sum of daily scores (ie, the maximum of morning and evening scores) divided by the number of days. The average daily score was calculated by using the 7 days pre-treatment for baseline, and the last 7 days of treatment for Week 13. A negative change from Baseline indicates that itch severity decreased.

    Time frame: Baseline to 13 weeks or end of treatment

07

Results

Posted Dec 7, 2015

Participant flow

Participant flow — Overall Study
MilestoneLUM001 140ug/kg/DayLUM001 280ug/kg/DayPlacebo Cohort APlacebo Cohort B
Started6833
Completed6832
Not completed0001
Withdrew: Adverse event0001

Outcome measures

PrimaryChange From Baseline to Week 13 (End of Treatment) in Fasting Serum Bile Acid Level

Participants were required to fast for at least 4 hours; only water was permitted prior to collection. A negative change from baseline indicates that the level of bile acid decreased.

Time frame:
Baseline to 13 weeks or end of treatment
Reported as:
Least squares mean · umol/L
Change From Baseline to Week 13 (End of Treatment) in Fasting Serum Bile Acid Level
umol/LLUM001 140ug/kg/DayLUM001 280ug/kg/DayLUM001 OverallPlacebo Overall
Change From Baseline to Week 13 (End of Treatment) in Fasting Serum Bile Acid Level-82.864 ± 50.1513-49.388 ± 43.4732-66.126 ± 33.1208-42.157 ± 50.0903
Statistical analysis
  • LUM001 140ug/kg/Day vs Placebo Overall · ANCOVA · p = 0.5740 · Ls mean difference from placebo: -40.707 · 95% CI -191.679 to 110.265
  • LUM001 280ug/kg/Day vs Placebo Overall · ANCOVA · p = 0.9147 · Ls mean difference from placebo: -7.231 · 95% CI -148.726 to 134.264
  • LUM001 Overall vs Placebo Overall · ANCOVA · p = 0.6954 · Ls mean difference from placebo: -23.969 · 95% CI -151.969 to 104.031
SecondaryChange From Baseline to Week 13 (End of Treatment) in Liver Enzymes

Analysis of liver enzymes included alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP). A negative change from baseline indicates that the level of that enzyme decreased.

Time frame:
Baseline to 13 weeks or end of treatment
Reported as:
Least squares mean · U/L
Change From Baseline to Week 13 (End of Treatment) in Liver Enzymes
U/LLUM001 140ug/kg/DayLUM001 280ug/kg/DayLUM001 OverallPlacebo Overall
ALT59.3 ± 20.9910.5 ± 18.0634.9 ± 13.862.7 ± 21.06
AST37.2 ± 13.64-2.7 ± 11.7017.3 ± 8.9813.2 ± 13.63
ALP71.4 ± 53.3531.6 ± 43.5951.5 ± 36.1319.7 ± 60.76
Statistical analysis
  • LUM001 140ug/kg/Day vs Placebo Overall · ANCOVA · p = 0.0783 · Ls mean difference from placebo: 56.7 · 95% CI -7.2 to 120.6
  • LUM001 280ug/kg/Day vs Placebo Overall · ANCOVA · p = 0.7827 · Ls mean difference from placebo: 7.8 · 95% CI -51.4 to 67.0
  • LUM001 Overall vs Placebo Overall · ANCOVA · p = 0.2235 · Ls mean difference from placebo: 32.2 · 95% CI -21.9 to 86.3
  • LUM001 140ug/kg/Day vs Placebo Overall · ANCOVA · p = 0.2372 · Ls mean difference from placebo: 24.0 · 95% CI -17.5 to 65.5
  • LUM001 280ug/kg/Day vs Placebo Overall · ANCOVA · p = 0.3914 · Ls mean difference from placebo: -15.8 · 95% CI -54.1 to 22.4
  • LUM001 Overall vs Placebo Overall · ANCOVA · p = 0.8081 · Ls mean difference from placebo: 4.1 · 95% CI -31.0 to 39.1
  • LUM001 140ug/kg/Day vs Placebo Overall · ANCOVA · p = 0.5748 · Ls mean difference from placebo: 51.7 · 95% CI -140.3 to 243.7
  • LUM001 280ug/kg/Day vs Placebo Overall · ANCOVA · p = 0.8835 · Ls mean difference from placebo: 11.9 · 95% CI -158.4 to 182.2
  • LUM001 Overall vs Placebo Overall · ANCOVA · p = 0.6917 · Ls mean difference from placebo: 31.8 · 95% CI -135.8 to 199.4
SecondaryChange From Baseline to Week 13 (End of Treatment) in Pruritus as Measured by The Patient And Observer Itch Reported Outcome (ItchRO) Average Daily Scores

The ItchRO was administered as a twice daily electronic diary (eDiary). Children ≥9 years of age completed the patient ItchRO; those between the ages of 5 and 8 completed the patient ItchRO with the assistance of their caregiver. There was no patient report for subjects under the age of 5. ItchRO scores range from 0 to 4, with the higher score indicating increasing itch severity. ItchRO average daily scores were calculated as the sum of daily scores (ie, the maximum of morning and evening scores) divided by the number of days. The average daily score was calculated by using the 7 days pre-treatment for baseline, and the last 7 days of treatment for Week 13. A negative change from Baseline indicates that itch severity decreased.

Time frame:
Baseline to 13 weeks or end of treatment
Reported as:
Least squares mean · units on a scale
Change From Baseline to Week 13 (End of Treatment) in Pruritus as Measured by The Patient And Observer Itch Reported Outcome (ItchRO) Average Daily Scores
units on a scaleLUM001 140ug/kg/DayLUM001 280ug/kg/DayLUM001 OverallPlacebo Overall
Patient ItchRO-1.159 ± 0.5396-0.608 ± 0.4399-0.883 ± 0.3484-0.811 ± 0.5684
Observer ItchRO-0.802 ± 0.2732-0.419 ± 0.2318-0.610 ± 0.1776-0.592 ± 0.2690
Statistical analysis
  • LUM001 140ug/kg/Day vs Placebo Overall · ANCOVA · p = 0.6907 · Ls mean difference from placebo: -0.348 · 95% CI -2.468 to 1.772
  • LUM001 280ug/kg/Day vs Placebo Overall · ANCOVA · p = 0.7897 · Ls mean difference from placebo: 0.202 · 95% CI -1.647 to 2.052
  • LUM001 Overall vs Placebo Overall · ANCOVA · p = 0.9203 · Ls mean difference from placebo: -0.073 · 95% CI -1.850 to 1.705
  • LUM001 140ug/kg/Day vs Placebo Overall · ANCOVA · p = 0.5966 · Ls mean difference from placebo: -0.210 · 95% CI -1.038 to 0.618
  • LUM001 280ug/kg/Day vs Placebo Overall · ANCOVA · p = 0.6320 · Ls mean difference from placebo: 0.173 · 95% CI -0.580 to 0.926
  • LUM001 Overall vs Placebo Overall · ANCOVA · p = 0.9547 · Ls mean difference from placebo: -0.019 · 95% CI -0.710 to 0.673

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LUM001 140ug/kg/Day—0/6 (0%)6/6 (100%)
LUM001 280ug/kg/Day—0/8 (0%)7/8 (87.5%)
Placebo Overall—0/6 (0%)4/6 (66.7%)
Most frequent other events
Showing 10 of 42
Most frequent other events
EventLUM001 140ug/kg/DayLUM001 280ug/kg/DayPlacebo Overall
DiarrhoeaGastrointestinal disorders4/65/82/6
Abdominal painGastrointestinal disorders1/65/81/6
Upper respiratory tract infectionInfections and infestations3/61/83/6
NasopharyngitisInfections and infestations2/61/81/6
HeadacheNervous system disorders2/61/80/6
VomitingGastrointestinal disorders0/62/81/6
Anal injuryInjury, poisoning and procedural complications0/62/80/6
Deafness unilateralEar and labyrinth disorders1/60/80/6
Ear painEar and labyrinth disorders1/60/80/6
Middle ear inflammationEar and labyrinth disorders1/60/80/6

Baseline characteristics

All randomized participants

Age, Continuous
Age, Continuous(years)LUM001 140ug/kg/DayLUM001 280ug/kg/DayPlacebo Cohort APlacebo Cohort BTotal
Mean5.8 ± 4.496.8 ± 6.735.0 ± 2.004.3 ± 3.215.9 ± 4.93
Age, Customized
Age, Customized(participants)LUM001 140ug/kg/DayLUM001 280ug/kg/DayPlacebo Cohort APlacebo Cohort BTotal
< 2 years03003
2 to 4 years31127
5 to 8 years11215
9 to 12 years20002
13 to 18 years03003
Sex: Female, Male
Sex: Female, Male(Participants)LUM001 140ug/kg/DayLUM001 280ug/kg/DayPlacebo Cohort APlacebo Cohort BTotal
Female233210
Male450110
Region of Enrollment
Region of Enrollment(participants)LUM001 140ug/kg/DayLUM001 280ug/kg/DayPlacebo Cohort APlacebo Cohort BTotal
United Kingdom683320
08

Study locations

3 sites
  • Birmingham Children's Hospital
    Birmingham, West Midlands B4 6NH, United Kingdom
  • Leeds Teaching Hospitals
    Leeds, West Yorkshire LS9 7TF, United Kingdom
  • Kings College Hospital
    London, SE5 9RS, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2013, a primary completion of Feb 2015 and a completion of Mar 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2015, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2013
First posted
Jul 19, 2013
Start
Aug 2013
Primary completionActual
Feb 2015
CompletionActual
Mar 2015
Results first posted
Dec 7, 2015
Last update
Mar 28, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 28, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01903460
Responsible party
Sponsor
First posted
Jul 19, 2013
Start date
Aug 2013
Primary completion
Feb 2015
Completion
Mar 2015
Results posted
Dec 7, 2015
Last update
Mar 28, 2019

Study contacts

Study Director
study director · Mirum

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Maralixibat

Start the discussion